

EXOMIND™

Postmenopause & Mental Wellness

Enhancing Mental Well-Being of Postmenopausal Women Using ExoTMS

Michelle Dees MD¹

1. Luxury Psychiatry Clinic., Winter Garden, FL, USA

Based on an article published in the Journal of Psychiatry and Psychiatric Disorders


DOI: 10.26502/jppd.2572-519X0255

Highlights


- 33 patients (25-78 years, BMI 17.5-43.1 kg/m²) seeking improvement in their mental well-being were enrolled in an IRB approved trial
- Out of these, 14 patients (50-78 years, BMI 19.0-28.3 kg/m²) were postmenopausal
- Patients received 4 Exomind treatments spaced 5-10 days apart
- Patients were evaluated using the Warwick-Edinburgh Mental Well-Being Scale (WEMWBS), Subject Satisfaction Questionnaire (SSQ), and Therapy Comfort Questionnaire (TCQ)
- 100% of all patients reported therapies as comfortable; no adverse events were reported



Patients reported feeling less depressed and anxious (SSQ) at 3-month follow-up



Patients reported feeling happier and having more mental energy (SSQ) at 3-month follow-up



Patients reported being more calm and focused (SSQ) at 3-month follow-up



Increase who achieved high mental well-being (WEMWBS) at 3-month follow-up compared to baseline



Patients who reported moderate mental well-being at baseline improved to high mental well-being (WEMWBS) at 3-month follow-up



Patients showed improved mental well-being scores (WEMWBS) at 3-month follow-up




Figure 1: Percentage of patients in individual categories according to WEMWBS scale.